Despite extensive knowledge of potential targets of SFN (Nrf2 induction and downregulation of NF-kB), and resulting modulation of intermediate endpoint biomarkers (apoptosis and proliferation) relevant to bladder carcinogenesis, these agents have not been evaluated in clinical trials for bladder cancer chemoprevention. The gene discussed is NFKB1; the disease is carcinoma.